Precursor Cell Lymphoblastic Leukemia-Lymphoma × Peripheral Blood Stem Cell Transplantation × Plasma cell × Clear all
NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Thomas Jefferson University

Phase 2 Completed
40 enrolled 15 charts
NCT03622788 2025-12-17

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
16 enrolled
NCT03333486 2025-07-04

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Roswell Park Cancer Institute

Phase 2 Terminated
31 enrolled 18 charts
NCT05805605 2025-07-01

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
56 enrolled
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT00611351 2023-10-23

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

University of Nebraska

Phase 2 Completed
5 enrolled 10 charts
NCT02960646 2023-02-16

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
11 enrolled
NCT00068523 2020-07-27

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

Phase NA Completed
10 enrolled
NCT00053989 2020-02-10

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Roswell Park Cancer Institute

Phase 2 Completed
41 enrolled 13 charts
NCT00040846 2020-01-29

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
60 enrolled 10 charts
NCT00089011 2020-01-29

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
150 enrolled 14 charts
NCT00006251 2020-01-21

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
21 enrolled
NCT00014235 2020-01-21

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase NA Completed
160 enrolled
NCT00078858 2020-01-18

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1/2 Completed
37 enrolled
NCT01527045 2020-01-02

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
47 enrolled 18 charts
NCT00003196 2019-12-27

Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma

Fred Hutchinson Cancer Center

Phase NA Completed
63 enrolled
NCT00027820 2019-12-20

Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
106 enrolled
NCT01251575 2019-12-09

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Completed
77 enrolled 10 charts
NCT00085449 2019-11-27

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
NCT00006350 2019-11-04

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

Phase 2 Completed
NCT00105001 2019-10-30

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
210 enrolled 15 charts
NCT01231412 2019-10-24

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 3 Completed
174 enrolled 12 charts
NCT00003396 2019-10-17

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

Phase 2 Completed
42 enrolled
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT00005799 2019-09-10

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Fred Hutchinson Cancer Center

Phase NA Completed
55 enrolled
NCT01116232 2019-03-26

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
4 enrolled 4 charts
NCT00453206 2018-09-10

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Wake Forest University Health Sciences

Phase NA Completed
66 enrolled 9 charts
NCT00619645 2018-01-10

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

University of California, Davis

Phase 2 Completed
8 enrolled 8 charts
NCT00245037 2017-09-27

Bu Flu TBI

OHSU Knight Cancer Institute

Phase 1/2 Completed
147 enrolled 19 charts
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT00448357 2017-07-17

LCCC0510

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Completed
54 enrolled 17 charts
NCT01076270 2017-06-28

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Fred Hutchinson Cancer Center

Phase NA Terminated
1 enrolled 7 charts
NCT00118352 2017-05-30

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
12 enrolled 10 charts
NCT00448201 2017-05-30

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
71 enrolled 12 charts
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00112593 2017-05-24

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

Fred Hutchinson Cancer Center

Phase NA Completed
5 enrolled 6 charts
NCT01427881 2017-05-19

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
43 enrolled 14 charts
NCT01118013 2017-03-24

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Alliance for Clinical Trials in Oncology

Phase 2 Terminated
6 enrolled 5 charts
NCT01652014 2016-07-14

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
NCT00079391 2015-10-26

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
50 enrolled 12 charts
NCT00716911 2015-06-08

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

City of Hope Medical Center

Phase NA Completed
100 enrolled
NCT00951626 2015-06-08

A Standardized Nursing Intervention Protocol for HCT Patients

City of Hope Medical Center

Phase NA Completed
282 enrolled
NCT00589563 2014-09-10

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

City of Hope Medical Center

Phase 2 Completed
32 enrolled 24 charts
NCT00008216 2014-06-06

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Columbia University

Terminated
48 enrolled
NCT00004145 2014-03-07

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Chicago

Phase 2 Completed
16 enrolled
NCT00003163 2014-01-06

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

National Cancer Institute (NCI)

Phase 2 Unknown
10 enrolled
NCT00008307 2014-01-06

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

National Cancer Institute (NCI)

Phase 2 Unknown
52 enrolled
NCT00295997 2014-01-06

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

National Cancer Institute (NCI)

Phase NA Unknown
35 enrolled
NCT00003425 2013-04-26

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

University of Kentucky

Phase 1/2 Completed
25 enrolled